PHOTO
- Patients can avail of blood tests anywhere with advanced turnkey solutions
Dubai: G42 Healthcare, a leading health-tech company on a mission to develop a world-class healthcare sector in the UAE and beyond, and Seegene Inc., a global biotechnology company specialising in molecular diagnostics, have signed a Memorandum of Understanding [MoU] to offer fully equipped mobile diagnostics and testing laboratories across the Middle East and North Africa [MENA] region.
The partnership will offer the innovative Seegene Mobile Station – a laboratory-on-wheels facility providing optimised molecular diagnosis and tests at any location to safeguard the health of communities.
The services will be on offer across MENA, including the UAE, Algeria, Morocco, Tunisia, Libya, Egypt, Sudan, Palestine, Jordan, Syria, Iraq, Iran, Pakistan, Lebanon, Kuwait, Qatar, Oman, Saudi Arabia, Bahrain, and Yemen.
The MoU was signed by Ashish Koshy, CEO of G42 Healthcare, and James Park, Seegene Executive Director during the Medlab Middle East Exhibition – MENA’s largest medical laboratory exhibition and congress underway at Dubai World Trade Center.
The Seegene Mobile Station conforms with the WHO guidelines of BioSafety Level-2 and offers automated testing with minimum supervision. It has all essential equipment, RT-PCR reagents, consumables, IT solutions, and technical support for diagnostic testing, is transportable by ship or land and can be made operational within few days.
In his comments, Ashish Koshy said: “We are proud to enter into a collaboration with Seegene which offers equitable access to healthcare anywhere in the Pan-Arab region. This is part of our joint efforts with international organisations to share our knowledge and expertise to future proof the health of nations.”
He added: “At G42 Healthcare, our commitment is to uphold patient health and reinforce our credentials as a transformation enabler in healthcare for the good of all humanity. The mobile testing services will further augment our business portfolio across the MENA region and help in reaching out to various markets, ensuring swift detection, and allowing patients to benefit from the most informed decision possible, regardless of the location.”
James Park, Seegene Executive Director, said: “Seegene is excited to be working with G42 Healthcare and contribute to the development of innovative solutions to bring healthy life for everyone by creating a new diagnostic paradigm. With this collaboration, we will join forces to serve the local communities with our expertise and resources. The Seegene Mobile Station will offer the most innovative mobile molecular diagnostic, testing and laboratory services and is part of our commitment to supporting the healthcare community in combatting COVID-19 infections, with a broad portfolio of research and development tools and diagnostics.”
He added: “The Mobile Station will significantly contribute to the mitigation efforts as it will help governments to control areas where epidemics spread easily and to place the laboratory near crowded places, such as community events.”
The Mobile Station also includes an equipment room and an extraction room. It encompasses a container with biosafety level-2 laboratory for the extraction room, collection device, instruments compatible with all Seegene assays, IT solution with Seegene Viewer, Reagent and Consumables, and technical support.
The all-in-one platform enables 2,000 tests per day including 225 pathogens in 10 different criteria and offers a streamlined automated workflow from pre-extraction to data analysis.
About G42 Healthcare
G42 Healthcare, a leading health-tech company, is on a mission to develop a world-class healthcare sector in the UAE and beyond, by harnessing data and advanced medical technologies to unlock the potential of personalized and preventive care and transforming the traditional healthcare ecosystem.
At the forefront in the battle against COVID-19, we have established Biogenix Labs, UAE’s first COVID-19 accredited large-scale throughput laboratory, facilitated the 4Humanity clinical trials, the world’s first phase three trial for inactivated vaccine against COVID-19 with over 43,000 volunteers from 125+ nationalities across the pan-Arab region, supported UAE’s healthcare authorities on the national vaccination implementation, employed advanced AI techniques and vast computing resources to accelerate the detection of COVID-19, conducted research into new vaccines and drug therapies, and built Omics Centre of Excellence, the region’s largest and most technologically advanced omics facility that is the backbone for the Emirati Genome Program, the world’s most comprehensive population genomics initiative.
Beyond COVID-19 we have plans and R&D encompassing genomics, imaging and diagnostics, and digitization programs to support the health of future generations. At G42 Healthcare, our plans are large in scale and bold in ambition. We partner extensively with governments, leading international entities, scientists and researchers and the wider medical community who subscribe to our values and our mission as we develop solutions to future-proof the health of nations.
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
